Partnership serves low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively.

Building on a collaboration launched in 2023, the renewed partnership reflects the organizations’ shared commitment to improving access to innovative cancer treatments in underserved communities. To date, the partnership has enabled access to BRUKINSA for more than 300 patients with CLL across Armenia, Ethiopia, and Nepal, exceeding the program’s original scope by approximately 150 patients and helping establish access to innovative cancer care for patients who previously had limited or no treatment options.

The collaboration combines The Max Foundation’s expertise in implementing oncology access programs with donated BRUKINSA from BeOne Medicines and a $1 million grant from the BeOne Care Foundation to support patient care, physician engagement, and operational infrastructure over the next two years.